Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.3 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:1. treatment of moderate to severe vasomotor symptoms associated with menopause. 2. treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.45 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.625 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.9 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 1.25 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - sildenafil as citrate 25 mg - film coated tablets - sildenafil - sildenafil teva ® 25 mg fc tablets is indicated for the treatment of erectile dysfunction.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - sildenafil as citrate 50 mg - film coated tablets - sildenafil - sildenafil teva® 50 mg fc tablets is indicated for the treatment of erectile dysfunction.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - amoxicillin trihydrate 250 mg - capsules - amoxicillin - infections caused by amoxicillin - susceptible organisms. prevention of bacteremia in patients at risk of developing bacterial endocarditis.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - cloxacillin as sodium - אבקה להכנת תמיסה לזריקה - cloxacillin as sodium 2 g/vial - cloxacillin - cloxacillin - for the treatment of infections caused by penicillinase-producing staphylococci. because of the high incidence of staphylococcal isolates resistant to penicillin g both within and outside the hospiral environment . orbenil is recommended as initial therapy in patients with suspected staphylococcal infections. orebenil is also effective in the treatment of other commonly encountered gram-positive coccal infections.typical indications include: - respiratory tract infections such as pneumonia and sinusitis - infected wounds and burns - osteomyelitis and septic arthritis - other infections due to staphylococci (including penicillin-resistant strains) such as septicemia endocarditis enterocolitis and urinary tract infections.

Ізраїль - іврит - Ministry of Health

salomon,levin & elstein ltd - cefonicide as sodium - אבקה להכנת תמיסה לזריקה - cefonicide as sodium 1000 mg/vial - cefonicide - cefonicide - treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to cefonicid.therapy with cefonicid may be initiated pending results of the studies however.treatment should be adjusted according to study findings. cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. in the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. surgical prophylaxis: the administration of a single 1 g. dose of cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providing protec